The FDA’s Endocrinologic and Metabolic Drugs and Drug Safety and Risk Management Advisory Committees will hold a joint meeting July 13-14 to discuss safety issues raised by 2 recent studies of GlaxoSmithKline’s diabetes medication Avandia (rosiglitazone). The studies link rosiglitazone use with a substantial increase in heart attack risk. Study researchers will present their findings to the FDA in July and have called for Avandia to be withdrawn from the market.